hVEGF-IN-1

Research use only, not for human use.

hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.

hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.

hVEGF-IN-1 (compound 1) (1 nM-100 μM; 5 min) binds to IRES-A (WT) and IRES-A mutant RNA oligomer (IRES-MU1) with Kds of 1.29 and 13.4 μM by microscale thermophoresis (MST) measurements, respectively. hVEGF-IN-1 (0.375-3 μM; 0-24 h) reduces MDA-MB-231 cell migration approximately 25% at the concentration of 3 μM.hVEGF-IN-1 (0.1875-3 μM; 48 h) reduces the level of VEGF-A protein in MCF-7 cells.hVEGF-IN-1 (0.375-3 μM; 48 h) decreases the relative wound closure of migrated MCF-7 cells by ～35% at the concentration of 3 μM.hVEGF-IN-1 (1.25-10 μM) reduces the stability of the IRES-A G-Quadruplex in a dose-dependent manner. Western Blot Analysis Cell Line:MCF-7 cells Concentration:0.1875, 0.375, 0.75, 1.5, 3 μM Incubation Time:48 hours Result:Down-regulated hVEGF-A expression.

hVEGF-IN-1 (compound 1) (7.5 mg/kg; i.p. once daily for 20 d) inhibits tumor growth in a human breast tumor xenograft. Animal Model:BALB/c female nude mice were implanted MCF-7 cells Dosage:7.5 mg/kg Administration:I.p. once daily for 20 days Result:Reduced the tumor volume to <300 mm3.Reduced the tumor weight around 60.1% to a final weight of 0.18 g.Decreased the VEGF-A level in tumor tissue.

——

Others

Other Targets

VEGF-A

——

——

1637443-98-1

581.75

C34H43N7O2

>98% (HPLC)

DMSO : 25 mg/mL42.97 mM;H2O : < 0.1 mg/mL

CCN(CC)CCOc1ccc(cc1)Nc1nc(c2c(NC(=O)CCN3CCN(C)CC3)cccc2)nc2ccccc12

——

(-20℃)

With Ice Pack

≥ 2 years